poisar

Stocks · News reference

Adaptive Biotechnologies Announces clonoSEQ Research Presentations for ASH 2026

Fiscal.ai

Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) will be featured in approximately 100 abstracts at the 68th Annual Meeting of the American Society of Hematology (ASH).

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading